Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. operated as a clinical-stage biotechnology company headquartered in Pittsburgh, Pennsylvania. The Company developed novel therapies using proprietary liposomal drug delivery technology and advanced multiple drug candidates into FDA-authorized clinical trials, including Phase 2 studies in oral lichen planus and hemorrhagic cystitis. The Company obtained multiple Investigational New Drug authorizations from the U.S. Food and Drug Administration.

In 2022, Lipella completed its initial public offering, and its common stock began trading on the Nasdaq Capital Market under the ticker symbol LIPO.

Between 2022 and 2026, the Company advanced multiple clinical development programs, reported Phase 2 results in hemhorragic cystitis and oral lichen planus, and expanded its intellectual property portfolio.

In June 2026, Lipella completed a court-approved sale of its pharmaceutical development programs, intellectual property, and regulatory assets to XRAIY LLC. The acquired programs are being pursued under the Kube Biosciences name. Following the transaction, Lipella concluded its research and development activities.

This website is maintained as the historical archive of Lipella Pharmaceuticals Inc. and as a source for corporate notices, announcements, SEC filings, publications, and other public disclosures.

Chapter 11 Plan and Disclosure Statement

The Disclosure Statement and accompanying Chapter 11 Plan of Liquidation of Lipella Pharmaceuticals Inc. are available at the following link.

Selected Publications

Corporate Information & Announcements

SEC Filings

Lipella Pharmaceuticals Inc.'s public filings are available through the SEC's EDGAR database:
View Lipella Pharmaceuticals Inc. SEC filings

Contact

Email: info@lipella.com

© 2026 Lipella Pharmaceuticals Inc.